This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

Trial Details

NCT ID

NCT07028853

Phase

PHASE3

Sponsor

Pfizer

Status

RECRUITING

Cancer Type

Hormone-Sensitive Prostate Cancer

Interventions

Mevrometostat
Placebo
Enzalutamide

Locations (sample)

Huntsville, Alabama, United States|34.7304,-86.58594
Huntsville, Alabama, United States|34.7304,-86.58594
Chandler, Arizona, United States|33.30616,-111.84125
Chandler, Arizona, United States|33.30616,-111.84125
Gilbert, Arizona, United States|33.35283,-111.78903

Key Eligibility Criteria

Male participants aged ≥18 years (or the minimum age of consent in accordance with local regulations) at screening.
Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features.
Metastatic prostate cancer documented by positive bone scan (for bone disease) or metastatic lesion(s) on CT or MRI (for soft tissue/visceral disea…
Resolution of acute effects of any prior therapy to either baseline severity or CTCAE Grade ≤1 (except for AEs which do not constitute a safety ris…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →